Another drop in the presbyopia bucket: Dr Bloomenstein shares his excitement for the FDA approval of Vizz

Published on August 6, 2025
With FDA approval of LENZ Therapeutics’ Vizz (LNZ100), optometrists now have a daily, non-invasive treatment option for presbyopia, giving patients more freedom and clinicians greater flexibility in care.
Continue reading on website
Other news

Alcon agrees to acquire STAAR Surgical

August 6, 2025
The planned acquisition of STAAR includes the EVO family of lenses (EVO ICL) for vision correction for patients with moderate to high myopia with or without astigmatism.

No Difference Seen in Risk of Sight-threatening DR Among GLP-1 Drugs

August 7, 2025
Given the rapidly increasing use of GLP-1 agonist pharmacotherapy, it is important to continue to improve our understanding of the impact of these powerful medications, as clinical trials have thus far provided limited and conflicting evidence on potential retinal risks. Photo: Novo Nordisk. Click image to enlarge.  The substantial increase in glucagon-like peptide-1 (GLP-1)